Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Erlotinib has been the only targeted agent to show significantly improved outcomes in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate whether the addition of oxaliplatin to a combination gemcitabine/erlotinib treatment conferred a clinical benefit in patients with locally advanced unresectable or metastatic pancreatic cancer. Materials and Methods: Chemotherapy-naïve patients with locally advanced or metastatic pancreatic cancer were randomly assigned to receive GEMOX-T [gemcitabine 1000 mg/m2 and oxaliplatin 50 mg/m2 on day 1 (D1) and D8 plus erlotinib 100 mg daily for 3 weeks] or GT (gemcitabine 1000 mg/m2 on D1 and D8 plus erlotinib 100 mg daily for 3 weeks). The primary endpoint was the overall response rate (ORR). Results: Between 2013 and 2016, 65 patients were assigned to a treatment group (33 in the GEMOX-T arm, 32 in the GT arm). The ORR was 18.2% [95% confidence interval (CI), 8.82–27.58] in the GEMOX-T arm and 6.2% (95% CI, 0.34–12.06) in the GT arm (p=0.051). The disease control rate was significantly superior in the GEMOX-T arm compared to the GT arm (72.7% vs. 43.8%, p=0.019). After a median follow-up of 19.7 months, the median progression-free survival (PFS) was 3.9 months for the GEMOX-T arm and 1.4 months for the GT arm (p=0.033). However, this did not translate to an improvement in overall survival. The most common grade 3 or higher hematologic adverse events were neutropenia (16.9%) and anemia (13.8%). Conclusion: The addition of oxaliplatin to a first-line gemcitabine/erlotinib regimen demonstrated higher response rates and significantly improved PFS in patients with locally advanced or metastatic pancreatic cancer.
Abstract
Purpose: Erlotinib has been the only targeted agent to show significantly improved outcomes in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate whether the addition of oxaliplatin to a combination gemcitabine/erlotinib treatment conferred a clinical benefit in patients with locally advanced unresectable or metastatic pancreatic cancer. Materials and Methods: Chemotherapy-naïve patients with locally advanced or metastatic pancreatic cancer were randomly assigned to receive GEMOX-T [gemcitabine 1000 mg/m2 and oxaliplatin 50 mg/m2 on day 1 (D1) and D8 plus erlotinib 100 mg daily for 3 weeks] or GT (gemcitabine 1000 mg/m2 on D1 and D8 plus erlotinib 100 mg daily for 3 weeks). The primary endpoint was the overall response rate (ORR). Results: Between 2013 and 2016, 65 patients were assigned to a treatment group (33 in the GEMOX-T arm, 32 in the GT arm). The ORR was 18.2% [95% confidence interval (CI), 8.82–27.58] in the GEMOX-T arm and 6.2% (95% CI, 0.34–12.06) in the GT arm (p=0.051). The disease control rate was significantly superior in the GEMOX-T arm compared to the GT arm (72.7% vs. 43.8%, p=0.019). After a median follow-up of 19.7 months, the median progression-free survival (PFS) was 3.9 months for the GEMOX-T arm and 1.4 months for the GT arm (p=0.033). However, this did not translate to an improvement in overall survival. The most common grade 3 or higher hematologic adverse events were neutropenia (16.9%) and anemia (13.8%). Conclusion: The addition of oxaliplatin to a first-line gemcitabine/erlotinib regimen demonstrated higher response rates and significantly improved PFS in patients with locally advanced or metastatic pancreatic cancer.
참고문헌 (20)
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
- Heinemann V, "Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer", J Clin Oncol, 24, pp.3946~3952 (2006)
- Louvet C, "Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer : results of a GERCOR and GISCAD phase III trial", J Clin Oncol, 23, pp.3509~3516 (2005)
- Oettle H, "A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer", Ann Oncol, 16, pp.1639~1645 (2005)
- Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
- Conroy T, "PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- Yun J, "A phase II study of gemcitabine, oxaliplatin, and erlotinib(GEMOX-T)combination chemotherapy in previously untreated patients with locally advanced unresectable or metastatic pancreatic cancer", J Clin Oncol, 32, pp.e15260~ (2014)
- Gonçalves A, "BAYPAN study : a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer", Ann Oncol, 23, pp.2799~2805 (2012)
- Kindler HL, "Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma : a doubleblind randomised phase 3 study", Lancet Oncol, 12, pp.256~262 (2011)
- Middleton G, "Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma(ViP) : a prospective, randomised, double-blind, multicentre phase 2 trial", Lancet Oncol, 18, pp.486~499 (2017)
- Philip PA, "Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma : Southwest Oncology Group-directed intergroup trial S0205", J Clin Oncol, 28, pp.3605~3610 (2010)
- Jones S, "Core signaling pathways in human pancreatic cancers revealed by global genomic analyses", Science, 321, pp.1801~1806 (2008)
- Irigoyen A, "Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer : efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group", Eur J Cancer, 75, pp.73~82 (2017)
- Van Cutsem E, "Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer : the phase II RACHEL study", Br J Cancer, 111, pp.2067~2075 (2014)
- Lee J, "Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer : a multicentre, open-label, randomised, phase 3study", Lancet Oncol, 13, pp.181~188 (2012)
- Zeng M, "Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib : a systematic review and meta-analysis", Onco Targets Ther, 11, pp.6633~6646 (2018)
- Mitsunaga S, "C-reactive protein level is an indicator of the aggressiveness of advanced pancreatic cancer", Pancreas, 45, pp.110~116 (2016)
- Middleton G, "Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer(TeloVac) : an open-label, randomised, phase 3trial", Lancet Oncol, 15, pp.829~840 (2014)